Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L HoNathan R FosterAlex J ZoroufyJordan D CampbellFrancis WordenKatharine PriceDouglas R AdkinsDaniel W BowlesHyunseok KangBarbara A BurtnessEric J ShermanRoscoe MortonLuc G T MorrisZaineb NadeemNora KatabiPamela N MunsterGary K SchwartzPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Enzalutamide demonstrated limited activity in AR+ SGC, failing to meet protocol-defined success in part because of a lack of response durability. Strategies to enhance the efficacy of antiandrogen therapy are needed.